The role of CD36 in the regulation of myocardial lipid metabolism

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 10, 2016, Pages 1450-1460

  Kim, Ty T ^a   Dyck, Jason R B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular disease; CD36; Fatty acid uptake; Lipid metabolism

Indexed keywords

CD36 ANTIGEN; FATTY ACID; INSULIN;

CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; DIABETIC CARDIOMYOPATHY; ENERGY METABOLISM; FATTY ACID TRANSPORT; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE METABOLISM; HUMAN; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; DIABETES MELLITUS; METABOLISM;

ANIMALS; ANTIGENS, CD36; DIABETES MELLITUS; HEART FAILURE; HUMANS; LIPID METABOLISM; MYOCARDIUM; REPERFUSION INJURY;

EID: 84962092270     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2016.03.018     Document Type: Review

References (153)

1. [1] Stanley, W.C., Recchia, F.A., Lopaschuk, G.D., Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005), 1093–1129.
2. [2] Lygate, C.A., Schneider, J.E., Neubauer, S., Investigating cardiac energetics in heart failure. Exp. Physiol. 98 (2013), 601–605.
3. [3] Fillmore, N., Lopaschuk, G.D., Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim. Biophys. Acta 1833 (2013), 857–865.
4. [4] Lopaschuk, G.D., Belke, D.D., Gamble, J., Itoi, T., Schonekess, B.O., Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim. Biophys. Acta 1213 (1994), 263–276.
5. [5] Carley, A.N., Bi, J., Wang, X., Banke, N.H., Dyck, J.R., O'Donnell, J.M., Lewandowski, E.D., Multiphasic triacylglycerol dynamics in the intact heart during acute in vivo overexpression of CD36. J. Lipid Res. 54 (2013), 97–106.
6. [6] Kienesberger, P.C., Pulinilkunnil, T., Sung, M.M., Nagendran, J., Haemmerle, G., Kershaw, E.E., Young, M.E., Light, P.E., Oudit, G.Y., Zechner, R., Dyck, J.R., Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol. Cell. Biol. 32 (2012), 740–750.
7. [7] Lahey, R., Wang, X., Carley, A.N., Lewandowski, E.D., Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 130 (2014), 1790–1799.
8. [8] van der Vusse, G.J., Glatz, J.F., Stam, H.C., Reneman, R.S., Fatty acid homeostasis in the normoxic and ischemic heart. Physiol. Rev. 72 (1992), 881–940.
9. [9] Haemmerle, G., Moustafa, T., Woelkart, G., Buttner, S., Schmidt, A., van de Weijer, T., Hesselink, M., Jaeger, D., Kienesberger, P.C., Zierler, K., Schreiber, R., Eichmann, T., Kolb, D., Kotzbeck, P., Schweiger, M., Kumari, M., Eder, S., Schoiswohl, G., Wongsiriroj, N., Pollak, N.M., Radner, F.P., Preiss-Landl, K., Kolbe, T., Rulicke, T., Pieske, B., Trauner, M., Lass, A., Zimmermann, R., Hoefler, G., Cinti, S., Kershaw, E.E., Schrauwen, P., Madeo, F., Mayer, B., Zechner, R., ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat. Med. 17 (2011), 1076–1085.
10. [10] Hue, L., Taegtmeyer, H., The Randle cycle revisited: a new head for an old hat. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E578–E591.
11. [11] Taegtmeyer, H., Golfman, L., Sharma, S., Razeghi, P., van Arsdall, M., Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann. N. Y. Acad. Sci. 1015 (2004), 202–213.
12. [12] Glatz, J.F., Bonen, A., Ouwens, D.M., Luiken, J.J., Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc. Drugs Ther. 20 (2006), 471–476.
13. [13] van der Vusse, G.J., Roemen, T.H., Prinzen, F.W., Coumans, W.A., Reneman, R.S., Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. Circ. Res. 50 (1982), 538–546.
14. [14] Ouwens, D.M., Diamant, M., Fodor, M., Habets, D.D., Pelsers, M.M., El Hasnaoui, M., Dang, Z.C., van den Brom, C.E., Vlasblom, R., Rietdijk, A., Boer, C., Coort, S.L., Glatz, J.F., Luiken, J.J., Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 50 (2007), 1938–1948.
15. [15] Chiu, H.C., Kovacs, A., Ford, D.A., Hsu, F.F., Garcia, R., Herrero, P., Saffitz, J.E., Schaffer, J.E., A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107 (2001), 813–822.
16. [16] Chiu, H.C., Kovacs, A., Blanton, R.M., Han, X., Courtois, M., Weinheimer, C.J., Yamada, K.A., Brunet, S., Xu, H., Nerbonne, J.M., Welch, M.J., Fettig, N.M., Sharp, T.L., Sambandam, N., Olson, K.M., Ory, D.S., Schaffer, J.E., Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96 (2005), 225–233.
17. [17] Carley, A.N., Severson, D.L., Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta 1734 (2005), 112–126.
18. [18] Lehman, J.J., Kelly, D.P., Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail. Rev. 7 (2002), 175–185.
19. [19] van Bilsen, M., Smeets, P.J., Gilde, A.J., van der Vusse, G.J., Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?. Cardiovasc. Res. 61 (2004), 218–226.
20. [20] Dyck, J.R., Lopaschuk, G.D., Malonyl CoA control of fatty acid oxidation in the ischemic heart. J. Mol. Cell. Cardiol. 34 (2002), 1099–1109.
21. [21] Lopaschuk, G.D., Metabolic abnormalities in the diabetic heart. Heart Fail. Rev. 7 (2002), 149–159.
22. [22] Unger, R.H., Orci, L., Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15 (2001), 312–321.
23. [23] Lakatta, E.G., Arterial pressure and aging. Int. J. Cardiol. 25:Suppl. 1 (1989), S81–S89.
24. [24] Liu, Q., Docherty, J.C., Rendell, J.C., Clanachan, A.S., Lopaschuk, G.D., High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J. Am. Coll. Cardiol. 39 (2002), 718–725.
25. [25] Chandler, M.P., Huang, H., McElfresh, T.A., Stanley, W.C., Increased nonoxidative glycolysis despite continued fatty acid uptake during demand-induced myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 282 (2002), H1871–H1878.
26. [26] Chandler, M.P., Chavez, P.N., McElfresh, T.A., Huang, H., Harmon, C.S., Stanley, W.C., Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc. Res. 59 (2003), 143–151.
27. [27] Lopaschuk, G.D., Barr, R., Thomas, P.D., Dyck, J.R., Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ. Res. 93 (2003), e33–e37.
28. [28] Mazumder, P.K., O'Neill, B.T., Roberts, M.W., Buchanan, J., Yun, U.J., Cooksey, R.C., Boudina, S., Abel, E.D., Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes, 53, 2004, 2366.
29. [29] Buchanan, J., Mazumder, P.K., Hu, P., Chakrabarti, G., Roberts, M.W., Yun, U.J., Cooksey, R.C., Litwin, S.E., Abel, E.D., Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005), 5341–5349.
30. [30] Boudina, S., Sena, S., O'Neill, B.T., Tathireddy, P., Young, M.E., Abel, E.D., Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation, 112, 2005, 2686.
31. [31] Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J.J., Hu, X.X., Aziz, S., Johnson, J.I., Bugger, H., Zaha, V.G., Abel, E.D., Mitochondrial energetics in the heart in obesity related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56 (2007), 2457–2466.
32. [32] Shen, X., Zheng, S., Metreveli, N.S., Epstein, P.N., Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55 (2006), 798–805.
33. [33] Shen, X., Zheng, S., Thongboonkerd, V., Xu, M., Pierce, W.M. Jr., Klein, J.B., Epstein, P.N., Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 287 (2004), E896–E905.
34. [34] Boudina, S., Abel, E.D., Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 21 (2006), 250–258.
35. [35] Fragasso, G., Salerno, A., Lattuada, G., Cuko, A., Calori, G., Scollo, A., Ragogna, F., Arioli, F., Bassanelli, G., Spoladore, R., Luzi, L., Margonato, A., Perseghin, G., Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart 97 (2011), 1495–1500.
36. [36] Jaswal, J.S., Keung, W., Wang, W., Ussher, J.R., Lopaschuk, G.D., Targeting fatty acid and carbohydrate oxidation–a novel therapeutic intervention in the ischemic and failing heart. Biochim. Biophys. Acta 1813 (2011), 1333–1350.
37. [37] Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90 (2010), 207–258.
38. [38] Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., Kratky, D., Wagner, E.F., Klingenspor, M., Hoefler, G., Zechner, R., Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312 (2006), 734–737.
39. [39] Kienesberger, P.C., Pulinilkunnil, T., Nagendran, J., Young, M.E., Bogner-Strauss, J.G., Hackl, H., Khadour, R., Heydari, E., Haemmerle, G., Zechner, R., Kershaw, E.E., Dyck, J.R., Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc. Res. 99 (2013), 442–451.
40. [40] Merkel, M., Eckel, R.H., Goldberg, I.J., Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43 (2002), 1997–2006.
41. [41] Duncan, J.G., Bharadwaj, K.G., Fong, J.L., Mitra, R., Sambandam, N., Courtois, M.R., Lavine, K.J., Goldberg, I.J., Kelly, D.P., Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation 121 (2010), 426–435.
42. [42] van der Vusse, G.J., van Bilsen, M., Glatz, J.F., Cardiac fatty acid uptake and transport in health and disease. Cardiovasc. Res. 45 (2000), 279–293.
43. [43] Coppiello, G., Collantes, M., Sirerol-Piquer, M.S., Vandenwijngaert, S., Schoors, S., Swinnen, M., Vandersmissen, I., Herijgers, P., Topal, B., van Loon, J., Goffin, J., Prosper, F., Carmeliet, P., Garcia-Verdugo, J.M., Janssens, S., Penuelas, I., Aranguren, X.L., Luttun, A., Meox2/Tcf15 heterodimers program the heart capillary endothelium for cardiac fatty acid uptake. Circulation 131 (2015), 815–826.
44. [44] Hamilton, J.A., Kamp, F., How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids?. Diabetes 48 (1999), 2255–2269.
45. [45] Hamilton, J.A., Fatty acid transport: difficult or easy?. J. Lipid Res. 39 (1998), 467–481.
46. [46] Abumrad, N., Harmon, C., Ibrahimi, A., Membrane transport of long-chain fatty acids: evidence for a facilitated process. J. Lipid Res. 39 (1998), 2309–2318.
47. [47] Rijzewijk, L.J., van der Meer, R.W., Smit, J.W., Diamant, M., Bax, J.J., Hammer, S., Romijn, J.A., de Roos, A., Lamb, H.J., Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 52 (2008), 1793–1799.
48. [48] Luiken, J.J., Dyck, D.J., Han, X.X., Tandon, N.N., Arumugam, Y., Glatz, J.F., Bonen, A., Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am. J. Physiol. Endocrinol. Metab. 282 (2002), E491–E495.
49. [49] Herrero, P., Peterson, L.R., McGill, J.B., Matthew, S., Lesniak, D., Dence, C., Gropler, R.J., Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J. Am. Coll. Cardiol. 47 (2006), 598–604.
50. [50] Greenwalt, D.E., Scheck, S.H., Rhinehart-Jones, T., Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J. Clin. Invest. 96 (1995), 1382–1388.
51. [51] Mashek, D.G., Coleman, R.A., Cellular fatty acid uptake: the contribution of metabolism. Curr. Opin. Lipidol. 17 (2006), 274–278.
52. [52] Glatz, J.F., Luiken, J.J., Bonen, A., Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev. 90 (2010), 367–417.
53. [53] Sung, M.M., Koonen, D.P., Soltys, C.L., Jacobs, R.L., Febbraio, M., Dyck, J.R., Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction. J. Mol. Med. 89 (2011), 459–469.
54. [54] Bonen, A., Benton, C.R., Campbell, S.E., Chabowski, A., Clarke, D.C., Han, X.X., Glatz, J.F., Luiken, J.J., Plasmalemmal fatty acid transport is regulated in heart and skeletal muscle by contraction, insulin and leptin, and in obesity and diabetes. Acta Physiol. Scand. 178 (2003), 347–356.
55. [55] Luiken, J.J., Schaap, F.G., van Nieuwenhoven, F.A., van der Vusse, G.J., Bonen, A., Glatz, J.F., Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids 34 Suppl (1999), S169–S175.
56. [56] Brinkmann, J.F., Abumrad, N.A., Ibrahimi, A., van der Vusse, G.J., Glatz, J.F., New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem. J. 367 (2002), 561–570.
57. [57] Gimeno, R.E., Fatty acid transport proteins. Curr. Opin. Lipidol. 18 (2007), 271–276.
58. [58] Habets, D.D., Coumans, W.A., Voshol, P.J., den Boer, M.A., Febbraio, M., Bonen, A., Glatz, J.F., Luiken, J.J., AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. Biochem. Biophys. Res. Commun. 355 (2007), 204–210.
59. [59] Weisiger, R.A., Cytosolic fatty acid binding proteins catalyze two distinct steps in intracellular transport of their ligands. Mol. Cell. Biochem. 239 (2002), 35–43.
60. [60] Ellis, J.M., Li, L.O., Wu, P.C., Koves, T.R., Ilkayeva, O., Stevens, R.D., Watkins, S.M., Muoio, D.M., Coleman, R.A., Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab. 12 (2010), 53–64.
61. [61] Steinbusch, L.K., Schwenk, R.W., Ouwens, D.M., Diamant, M., Glatz, J.F., Luiken, J.J., Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell. Mol. Life Sci. 68 (2011), 2525–2538.
62. [62] Coburn, C.T., Knapp, F.F. Jr., Febbraio, M., Beets, A.L., Silverstein, R.L., Abumrad, N.A., Defective uptake and utilization of long-chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem. 275 (2000), 32523–32529.
63. [63] Abumrad, N.A., el-Maghrabi, R., Amri, E.Z., Lopez, E., grimaldi, P.A., Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 268 (1993), 17665–17668.
64. [64] Schaffer, J.E., Lodish, H.F., Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein [see comments]. Cell 79 (1994), 427–436.
65. [65] Sorrentino, D., Stump, D., Potter, B.J., Robinson, R.B., White, R., Kiang, C.L., Berk, P.D., Oleate uptake by cardiac myocytes is carrier mediated and involves a 40-kD plasma membrane fatty acid binding protein similar to that in liver, adipose tissue, and gut. J. Clin. Invest. 82 (1988), 928–935.
66. [66] Gimeno, R.E., Ortegon, A.M., Patel, S., Punreddy, S., Ge, P., Sun, Y., Lodish, H.F., Stahl, A., Characterization of a heart-specific fatty acid transport protein. J. Biol. Chem. 278 (2003), 16039–16044.
67. [67] Ibrahimi, A., Abumrad, N.A., Role of CD36 in membrane transport of long-chain fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002), 139–145.
68. [68] Luiken, J.J., Glatz, J.F., Bonen, A., Fatty acid transport proteins facilitate fatty acid uptake in skeletal muscle. Can. J. Appl. Physiol. 25 (2000), 333–352.
69. [69] Jay, A.G., Chen, A.N., Paz, M.A., Hung, J.P., Hamilton, J.A., CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding. J. Biol. Chem. 290 (2015), 4590–4603.
70. [70] Greenwalt, D.E., Lipsky, R.H., Ockenhouse, C.F., Ikeda, H., Tandon, N.N., Jamieson, G.A., Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood, 80, 1992, 1105.
71. [71] Talle, M.A., Allegar, N., Makowski, M., Rao, P.E., Mittler, R.S., Goldstein, G., Classification of human lymphocytes and monocytes with the OK series of monoclonal antibodies. Diagn. Immunol. 1 (1983), 129–135.
72. [72] Li, Y.S., Shyy, Y.J., Wright, J.G., Valente, A.J., Cornhill, J.F., Kolattukudy, P.E., The expression of monocyte chemotactic protein (MCP-1) in human vascular endothelium in vitro and in vivo. Mol. Cell. Biochem. 126 (1993), 61–68.
73. [73] Schubert, W., Triple immunofluorescence confocal laser scanning microscopy: spatial correlation of novel cellular differentiation markers in human muscle biopsies. Eur. J. Cell Biol. 55 (1991), 272–285.
74. [74] Van Nieuwenhoven, F.A., Verstijnen, C.P., Abumrad, N.A., Willemsen, P.H., Van Eys, G.J., Van der Vusse, G.J., Glatz, J.F., Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem. Biophys. Res. Commun. 207 (1995), 747–752.
75. [75] Febbraio, M., Hajjar, D.P., Silverstein, R.L., CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108 (2001), 785–791.
76. [76] Febbraio, M., Abumrad, N.A., Hajjar, D.P., Sharma, K., Cheng, W., Pearce, S.F., Silverstein, R.L., A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274 (1999), 19055–19062.
77. [77] Angin, Y., Steinbusch, L.K., Simons, P.J., Greulich, S., Hoebers, N.T., Douma, K., van Zandvoort, M.A., Coumans, W.A., Wijnen, W., Diamant, M., Ouwens, D.M., Glatz, J.F., Luiken, J.J., CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem. J. 448 (2012), 43–53.
78. [78] van Oort, M.M., van Doorn, J.M., Bonen, A., Glatz, J.F., van der Horst, D.J., Rodenburg, K.W., Luiken, J.J., Insulin-induced translocation of CD36 to the plasma membrane is reversible and shows similarity to that of GLUT4. Biochim. Biophys. Acta 1781 (2008), 61–71.
79. [79] Muller, H., Deckers, K., Eckel, J., The fatty acid translocase (FAT)/CD36 and the glucose transporter GLUT4 are localized in different cellular compartments in rat cardiac muscle. Biochem. Biophys. Res. Commun. 293 (2002), 665–669.
80. [80] Glatz, J.F., Angin, Y., Steinbusch, L.K., Schwenk, R.W., Luiken, J.J., CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Prostaglandins Leukot. Essent. Fat. Acids 88 (2013), 71–77.
81. [81] Kim, T.T., Dyck, J.R., Is AMPK the savior of the failing heart?. Trends Endocrinol. Metab. 26 (2015), 40–48.
82. [82] Luiken, J.J., Ouwens, D.M., Habets, D.D., van der Zon, G.C., Coumans, W.A., Schwenk, R.W., Bonen, A., Glatz, J.F., Permissive action of protein kinase C-zeta in insulin-induced CD36- and GLUT4 translocation in cardiac myocytes. J. Endocrinol. 201 (2009), 199–209.
83. [83] Ronnebaum, S.M., Patterson, C., The FoxO family in cardiac function and dysfunction. Annu. Rev. Physiol. 72 (2010), 81–94.
84. [84] Mungai, P.T., Waypa, G.B., Jairaman, A., Prakriya, M., Dokic, D., Ball, M.K., Schumacker, P.T., Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol. Cell. Biol. 31 (2011), 3531–3545.
85. [85] Dyck, J.R., Lopaschuk, G.D., AMPK alterations in cardiac physiology and pathology: enemy or ally?. J. Physiol. 574 (2006), 95–112.
86. [86] Luiken, J.J., Coort, S.L., Willems, J., Coumans, W.A., Bonen, A., van der Vusse, G.J., Glatz, J.F., Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52 (2003), 1627–1634.
87. [87] Philip-Couderc, P., Tavares, N.I., Roatti, A., Lerch, R., Montessuit, C., Baertschi, A.J., Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism. Circ. Res. 102 (2008), e20–e35.
88. [88] Okamoto, F., Tanaka, T., Sohmiya, K., Kawamura, K., CD36 abnormality and impaired myocardial long-chain fatty acid uptake in patients with hypertrophic cardiomyopathy. Jpn. Circ. J. 62 (1998), 499–504.
89. [89] Tanaka, T., Nakata, T., Oka, T., Ogawa, T., Okamoto, F., Kusaka, Y., Sohmiya, K., Shimamoto, K., Itakura, K., Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J. Lipid Res. 42 (2001), 751–759.
90. [90] Rac, M.E., Safranow, K., Poncyljusz, W., Molecular basis of human CD36 gene mutations. Mol. Med. 13 (2007), 288–296.
91. [91] Hall, D., Mayosi, B.M., Rahman, T.J., Avery, P.J., Watkins, H.C., Keavney, B., Common variation in the CD36 (fatty acid translocase) gene is associated with left-ventricular mass. J. Hypertens. 29 (2011), 690–695.
92. [92] Aasum, E., Cooper, M., Severson, D.L., Larsen, T.S., Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can. J. Physiol. Pharmacol. 83 (2005), 183–190.
93. [93] Lauzier, B., Merlen, C., Vaillant, F., McDuff, J., Bouchard, B., Beguin, P.C., Dolinsky, V.W., Foisy, S., Villeneuve, L.R., Labarthe, F., Dyck, J.R., Allen, B.G., Charron, G., Des Rosiers, C., Post-translational modifications, a key process in CD36 function: lessons from the spontaneously hypertensive rat heart. J. Mol. Cell. Cardiol. 51 (2011), 99–108.
94. [94] Pietka, T.A., Sulkin, M.S., Kuda, O., Wang, W., Zhou, D., Yamada, K.A., Yang, K., Su, X., Gross, R.W., Nerbonne, J.M., Efimov, I.R., Abumrad, N.A., CD36 protein influences myocardial Ca2 + homeostasis and phospholipid metabolism: conduction anomalies in CD36-deficient mice during fasting. J. Biol. Chem. 287 (2012), 38901–38912.
95. [95] Irie, H., Krukenkamp, I.B., Brinkmann, J.F., Gaudette, G.R., Saltman, A.E., Jou, W., Glatz, J.F., Abumrad, N.A., Ibrahimi, A., Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 6819–6824.
96. [96] Nagendran, J., Waller, T.J., Dyck, J.R., AMPK signalling and the control of substrate use in the heart. Mol. Cell. Endocrinol. 366 (2013), 180–193.
97. [97] Kantor, P.F., Dyck, J.R., Lopaschuk, G.D., Fatty acid oxidation in the reperfused ischemic heart. Am. J. Med. Sci. 318 (1999), 3–14.
98. [98] Frank, A., Bonney, M., Bonney, S., Weitzel, L., Koeppen, M., Eckle, T., Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin. Cardiothorac. Vasc. Anesth. 16 (2012), 123–132.
99. [99] Kurien, V.A., Oliver, M.F., Free fatty acids during acute myocardial infarction. Prog. Cardiovasc. Dis. 13 (1971), 361–373.
100. [100] Lopaschuk, G.D., Collins-Nakai, R., Olley, P.M., Montague, T.J., McNeil, G., Gayle, M., Penkoske, P., Finegan, B.A., Plasma fatty acid levels in infants and adults after myocardial ischemia. Am. Heart J. 128 (1994), 61–67.
101. [101] Mueller, H.S., Ayres, S.M., Metabolic response of the heart in acute myocardial infarction in man. Am. J. Cardiol. 42 (1978), 363–371.
102. [102] Dolinsky, V.W., Dyck, J.R., Role of AMP-activated protein kinase in healthy and diseased hearts. Am. J. Physiol. Heart Circ. Physiol. 291 (2006), H2557–H2569.
103. [103] Fillmore, N., Mori, J., Lopaschuk, G.D., Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br. J. Pharmacol. 171 (2014), 2080–2090.
104. [104] Liedtke, A.J., DeMaison, L., Eggleston, A.M., Cohen, L.M., Nellis, S.H., Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ. Res. 62 (1988), 535–542.
105. [105] Hendrickson, S.C., Louis, J.D.St., Lowe, J.E., Abdel-aleem, S., Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol. Cell. Biochem. 166 (1997), 85–94.
106. [106] Lopaschuk, G.D., Spafford, M.A., Davies, N.J., Wall, S.R., Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ. Res. 66 (1990), 546–553.
107. [107] Lopaschuk, G.D., Stanley, W.C., Glucose metabolism in the ischemic heart. Circulation 95 (1997), 313–315.
108. [108] Mjos, O.D., Ichihara, K., Fellenius, E., Myrmel, T., Neely, J.R., Fatty acids suppress recovery of heart function after hypothermic perfusion. Ann. Thorac. Surg. 52 (1991), 965–970.
109. [109] Heather, L.C., Pates, K.M., Atherton, H.J., Cole, M.A., Ball, D.R., Evans, R.D., Glatz, J.F., Luiken, J.J., Griffin, J.L., Clarke, K., Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion. Circ. Heart Fail. 6 (2013), 1058–1066.
110. [110] Lazar, H.L., Alterations in myocardial metabolism in the diabetic myocardium. Semin. Thorac. Cardiovasc. Surg. 18 (2006), 289–292.
111. [111] Bessi, V.L., Labbe, S.M., Huynh, D.N., Menard, L., Jossart, C., Febbraio, M., Guerin, B., Bentourkia, M., Lecomte, R., Carpentier, A.C., Ong, H., Marleau, S., EP 80317, a selective CD36 ligand, shows cardioprotective effects against post-ischaemic myocardial damage in mice. Cardiovasc. Res. 96 (2012), 99–108.
112. [112] Kuang, M., Febbraio, M., Wagg, C., Lopaschuk, G.D., Dyck, J.R., Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109 (2004), 1550–1557.
113. [113] Nagendran, J., Pulinilkunnil, T., Kienesberger, P.C., Sung, M.M., Fung, D., Febbraio, M., Dyck, J.R., Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery. J. Mol. Cell. Cardiol. 63 (2013), 180–188.
114. [114] Lowe, L.P., Liu, K., Greenland, P., Metzger, B.E., Dyer, A.R., Stamler, J., Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care, 20, 1997, 163.
115. [115] Lteif, A.A., Mather, K.J., Clark, C.M., Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. Cardiol. Rev., 11, 2003, 262.
116. [116] Boudina, S., Abel, E.D., Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 11 (2010), 31–39.
117. [117] Postic, C., Mauvais-Jarvis, F., Girard, J., Mouse models of insulin resistance and type 2 diabetes. Ann. Endocrinol. 65 (2004), 51–59.
118. [118] Kloting, I., Berg, S., Kovacs, P., Voigt, B., Vogt, L., Schmidt, S., Diabetes and hypertension in rodent models. Ann. N. Y. Acad. Sci. 827 (1997), 64–84.
119. [119] Echtay, K.S., Roussel, D., St-Pierre, J., Jekabsons, M.B., Cadenas, S., Stuart, J.A., Harper, J.A., Roebuck, S.J., Morrison, A., Pickering, S., Clapham, J.C., Brand, M.D., Superoxide activates mitochondrial uncoupling proteins. Nature 415 (2002), 96–99.
120. [120] Ye, G., Metreveli, N.S., Ren, J., Epstein, P.N., Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52 (2003), 777–783.
121. [121] Pulinilkunnil, T., Rodrigues, B., Cardiac lipoprotein lipase: metabolic basis for diabetic heart disease. Cardiovasc. Res. 69 (2006), 329–340.
122. [122] Stanley, W.C., Lopaschuk, G.D., McCormack, J.G., Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 34 (1997), 25–33.
123. [123] Luiken, J.J., Koonen, D.P., Willems, J., Zorzano, A., Becker, C., Fischer, Y., Tandon, N.N., Van Der Vusse, G.J., Bonen, A., Glatz, J.F., Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51 (2002), 3113–3119.
124. [124] Luiken, J.J., Bonen, A., Glatz, J.F., Alterations in muscular fatty acid handling in diabetes. Adv. Mol. Cell Biol. 33 (2003), 243–258.
125. [125] Griffin, E., Re, A., Hamel, N., Fu, C., Bush, H., McCaffrey, T., Asch, A.S., A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat. Med. 7 (2001), 840–846.
126. [126] Unger, R.H., Orci, L., Lipotoxic diseases of nonadipose tissues in obesity. Int. J. Obes. Relat. Metab. Disord. 24:Suppl. 4 (2000), S28–S32.
127. [127] Carley, A.N., Semeniuk, L.M., Shimoni, Y., Aasum, E., Larsen, T.S., Berger, J.P., Severson, D.L., Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am. J. Physiol. Endocrinol. Metab. 286 (2004), E449–E455.
128. [128] Young, M.E., Guthrie, P.H., Razeghi, P., Leighton, B., Abbasi, S., Patil, S., Youker, K.A., Taegtmeyer, H., Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes, 51, 2002, 2587.
129. [129] Listenberger, L.L., Schaffer, J.E., Mechanisms of lipoapoptosis: implications for human heart disease. Trends Cardiovasc. Med. 12 (2002), 134–138.
130. [130] Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V. Jr., Ory, D.S., Schaffer, J.E., Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 3077–3082.
131. [131] McGavock, J.M., Victor, R.G., Unger, R.H., Szczepaniak, L.S., Adiposity of the heart, revisited. Ann. Intern. Med. 144 (2006), 517–524.
132. [132] Luiken, J.J., Arumugam, Y., Dyck, D.J., Bell, R.C., Pelsers, M.M., Turcotte, L.P., Tandon, N.N., Glatz, J.F., Bonen, A., Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J. Biol. Chem. 276 (2001), 40567–40573.
133. [133] Yang, J., Sambandam, N., Han, X., Gross, R.W., Courtois, M., Kovacs, A., Febbraio, M., Finck, B.N., Kelly, D.P., CD36 deficiency rescues lipotoxic cardiomyopathy. Circ. Res. 100 (2007), 1208–1217.
134. [134] Sambandam, N., Lopaschuk, G.D., Brownsey, R.W., Allard, M.F., Energy metabolism in the hypertrophied heart. Heart Fail. Rev. 7 (2002), 161–173.
135. [135] Wambolt, R.B., Henning, S.L., English, D.R., Dyachkova, Y., Lopaschuk, G.D., Allard, M.F., Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. J. Mol. Cell. Cardiol. 31 (1999), 493–502.
136. [136] Allard, M.F., Wambolt, R.B., Longnus, S.L., Grist, M., Lydell, C.P., Parsons, H.L., Rodrigues, B., Hall, J.L., Stanley, W.C., Bondy, G.P., Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am. J. Physiol. Endocrinol. Metab. 279 (2000), E487–E493.
137. [137] Wambolt, R.B., Lopaschuk, G.D., Brownsey, R.W., Allard, M.F., Dichloroacetate improves postischemic function of hypertrophied rat hearts. J. Am. Coll. Cardiol. 36 (2000), 1378–1385.
138. [138] Longnus, S.L., Wambolt, R.B., Barr, R.L., Lopaschuk, G.D., Allard, M.F., Regulation of myocardial fatty acid oxidation by substrate supply. Am. J. Physiol. Heart Circ. Physiol. 281 (2001), H1561–H1567.
139. [139] Allard, M.F., Lopaschuk, G.D., Ischemia and reperfusion injury in the hypertrophied heart. EXS 76 (1996), 423–441.
140. [140] Allard, M.F., Schonekess, B.O., Henning, S.L., English, D.R., Lopaschuk, G.D., Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Phys. 267 (1994), H742–H750.
141. [141] Watanabe, K., Toba, K., Ogawa, Y., Kodama, M., Hirono, S., Ohkura, Y., Hanawa, H., Nakamura, Y., Aoki, Y., Fuse, I., Aizawa, Y., Miyajima, S., Kusano, Y., Nagatomo, T., Hasegawa, G., Naito, M., Hypertrophic cardiomyopathy with type I CD36 deficiency. Jpn. Circ. J. 62 (1998), 541–542.
142. [142] Tanaka, T., Sohmiya, K., Kawamura, K., Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?. J. Mol. Cell. Cardiol. 29 (1997), 121–127.
143. [143] Cheng, L., Ding, G., Qin, Q., Huang, Y., Lewis, W., He, N., Evans, R.M., Schneider, M.D., Brako, F.A., Xiao, Y., Chen, Y.E., Yang, Q., Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10 (2004), 1245–1250.
144. [144] Ingwall, J.S., Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 81 (2009), 412–419.
145. [145] Hajri, T., Ibrahimi, A., Coburn, C.T., Knapp, F.F. Jr., Kurtz, T., Pravenec, M., Abumrad, N.A., Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J. Biol. Chem. 276 (2001), 23661–23666.
146. [146] Ouwens, D.M., Boer, C., Fodor, M., de Galan, P., Heine, R.J., Maassen, J.A., Diamant, M., Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 48 (2005), 1229–1237.
147. [147] Steinbusch, L.K., Luiken, J.J., Vlasblom, R., Chabowski, A., Hoebers, N.T., Coumans, W.A., Vroegrijk, I.O., Voshol, P.J., Ouwens, D.M., Glatz, J.F., Diamant, M., Absence of fatty acid transporter CD36 protects against Western-type diet-related cardiac dysfunction following pressure overload in mice. Am. J. Physiol. Endocrinol. Metab. 301 (2011), E618–E627.
148. [148] Chess, D.J., Lei, B., Hoit, B.D., Azimzadeh, A.M., Stanley, W.C., Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload. J. Card. Fail. 14 (2008), 82–88.
149. [149] Sabbah, H.N., Chandler, M.P., Mishima, T., Suzuki, G., Chaudhry, P., Nass, O., Biesiadecki, B.J., Blackburn, B., Wolff, A., Stanley, W.C., Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fail. 8 (2002), 416–422.
150. [150] Chandler, M.P., Stanley, W.C., Morita, H., Suzuki, G., Roth, B.A., Blackburn, B., Wolff, A., Sabbah, H.N., Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ. Res. 91 (2002), 278–280.
151. [151] Imai, M., Rastogi, S., Sharma, N., Chandler, M.P., Sharov, V.G., Blackburn, B., Belardinelli, L., Stanley, W.C., Sabbah, H.N., CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure. Cardiovasc. Drugs Ther. 21 (2007), 9–15.
152. [152] Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, J., Dai, S., Ford, E.S., Fox, C.S., Franco, S., Fullerton, H.J., Gillespie, C., Hailpern, S.M., Heit, J.A., Howard, V.J., Huffman, M.D., Judd, S.E., Kissela, B.M., Kittner, S.J., Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Mackey, R.H., Magid, D.J., Marcus, G.M., Marelli, A., Matchar, D.B., McGuire, D.K., Mohler, E.R. 3rd, Moy, C.S., Mussolino, M.E., Neumar, R.W., Nichol, G., Pandey, D.K., Paynter, N.P., Reeves, M.J., Sorlie, P.D., Stein, J., Towfighi, A., Turan, T.N., Virani, S.S., Wong, N.D., Woo, D., Turner, M.B., C. American Heart Association Statistics, S. Stroke Statistics, Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 129 (2014), e28–e292.
153. [153] Neubauer, S., The failing heart–an engine out of fuel. N. Engl. J. Med. 356 (2007), 1140–1151.